Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013
about
Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program.Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-AvibactamIn Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008-14: results from the Study for Monitoring Antimicrobial ResistaIn vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014.In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.Extended-spectrum β-lactamase-producing Escherichia coli in wastewaters and refugee camp in Lebanon.Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program.Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015Ertapenem non-susceptibility and independent predictors of the carbapenemase production among the Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistanc
P2860
Q36571962-2E091154-67B2-4780-BF7A-8AB0105AB492Q36644582-830084AA-927F-46AC-9FE0-E95611E583B4Q36887866-D9D1B239-F791-44FB-8E22-078390BB68EAQ36888062-6EB94B33-E28F-4711-B70C-39FFF1BFC391Q37119944-92185039-A929-4310-85D2-BFC0556234D7Q37120019-CF5734E7-7D28-4EF5-846B-07236798A826Q37120182-481938FF-A758-4FEF-97AD-84E3DCBB81A8Q37363425-F2951B6D-7773-416D-9A5C-A308B002F444Q38864569-126BD22C-5977-40B2-9E6D-DAA474590E0DQ40166206-ED46CA50-A693-4F68-BEB4-48A06AB150CFQ40287334-A808D0FF-57AE-41D0-AE2E-6219BB12A166Q40517201-5D07340A-E969-446E-A009-5E36F5E09573Q41240109-BC93CCFD-7822-4E5E-BCE7-2FA9522AEE4DQ45223510-A261CEBE-16AA-4E07-837F-EDE8B4FEC9C3Q47129277-34CF1635-0239-4F4A-B71F-C240CB139EF2Q47789784-2DD23CF5-4764-44FB-8627-3E42A363AD8EQ53699378-699D91C6-3094-4C70-9E73-83F202F0CEA1Q57211457-AA119DEB-2255-4C62-BDE5-A3ABEC0AE2C7Q58694593-FBC8A4C9-005F-4643-95F0-A430E1EC3BC0
P2860
Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Trends in susceptibility of Es ...... he SMART program, 2009 to 2013
@ast
Trends in susceptibility of Es ...... he SMART program, 2009 to 2013
@en
type
label
Trends in susceptibility of Es ...... he SMART program, 2009 to 2013
@ast
Trends in susceptibility of Es ...... he SMART program, 2009 to 2013
@en
prefLabel
Trends in susceptibility of Es ...... he SMART program, 2009 to 2013
@ast
Trends in susceptibility of Es ...... he SMART program, 2009 to 2013
@en
P2093
P2860
P356
P1476
Trends in susceptibility of Es ...... he SMART program, 2009 to 2013
@en
P2093
Daniel F Sahm
Douglas J Biedenbach
Krystyna M Kazmierczak
Meredith A Hackel
Robert E Badal
Samuel K Bouchillon
Sibylle H Lob
P2860
P304
P356
10.1128/AAC.05186-14
P407
P577
2015-03-23T00:00:00Z